Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months’ follow-up: an optical coherence tomography study

详细信息    查看全文

• 作者：Takehiro Hashikata ; Taiki Tojo ; Sayaka Namba ; Lisa Kitasato…
• 关键词：Zotarolimus eluting stent ; Stent thrombosis ; Neointimal coverage ; Optical coherence tomography
• 刊名：Heart and Vessels
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：31
• 期：2
• 页码：206-211
• 全文大小：554 KB
• 参考文献：1.Stefanini GG, Holmes DR Jr (2013) Drug-eluting coronary-artery stents. N Engl J Med 368:254–265CrossRef PubMed
  2.Udipi K, Chen M, Cheng P, Jiang K, Judd D, Caceres A, Melder RJ, Wilcox JN (2008) Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A 85:1064–1071CrossRef PubMed
  3.Widimsky P, Motovska Z, Belardi J, Serruys P, Silber S, Windecker S, Neumann FJ (2013) Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program. Int J Cardiol 168:3522–3526CrossRef PubMed
  4.Jim MH, Yiu KH, Fung RC, Ho HH, Ng AK, Siu CW, Chow WH (2014) Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS). Heart Vessels 29:29–34CrossRef PubMed
  5.Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S (2014) Four year clinical outcomes and predictors of repeat revascularization in patients treated with new generation drug-eluting stents in the RESOLUTE all comers randomized trial. J Am Coll Cardiol 63:1617–1625CrossRef PubMed
  6.Silber S, Kirtane AJ, Belardi JA, Liu M, Brar S, Rothman M, Windecker S (2014) Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 35:1949–1956CrossRef PubMed
  7.Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, Ladich E, Lortkipanidze N, Matiashvili A, Valsecchi O, Virmani R, Stone GW (2012) Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv 5:12–20CrossRef PubMed
  8.Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R (2007) Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115:2435–2441CrossRef PubMed
  9.Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nuesch E, Garcia-Garcia HM, Silber S, Windecker S, Serruys PW (2011) Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE all comers trial. Eur Heart J 32:2454–2463PubMedCentral CrossRef PubMed
  10.Ikuta S, Kobuke K, Iwanaga Y, Nakauchi Y, Yamaji K, Miyazaki S (2014) Difference in neointimal coverage at chronic stage between bare metal stent and sirolimus-eluting stent evaluated at stent-strut level by optical coherence tomography. Heart Vessels 29:320–327CrossRef PubMed
  11.Tada T, Byrne RA, Schuster T, Cuni R, Kitabata H, Tiroch K, Dirninger A, Gratze F, Kaspar K, Zenker G, Joner M, Schomig A, Kastrati A (2013) Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. Cardiovasc Revasc Med 14:84–89CrossRef PubMed
  12.Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, Ohba T, Mizuno K (2007) Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent 3 months after implantation. Am J Cardiol 99:1033–1038CrossRef PubMed
  13.Guagliumi G, Musumeci G, Sirbu V, Bezerra HG, Suzuki N, Fiocca L, Matiashvili A, Lortkipanidze N, Trivisonno A, Valsecchi O, Biondi-Zoccai G, Costa MA (2010) Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents. JACC Cardiovasc Interv 3:531–539CrossRef PubMed
  14.Kim JS, Jang IK, Kim JS, Kim TH, Takano M, Kume T, Hur NW, Ko YG, Choi D, Hong MK, Jang Y (2009) Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 95:1907–1912PubMedCentral CrossRef PubMed
  15.Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, Toyota E, Neishi Y, Sukmawan R, Sadahira Y, Yoshida K (2006) Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 97:1713–1717CrossRef PubMed
  16.Templin C, Meyer M, Muller MF, Djonov V, Hlushchuk R, Dimova I, Flueckiger S, Kronen P, Sidler M, Klein K, Nicholls F, Ghadri JR, Weber K, Paunovic D, Corti R, Hoerstrup SP, Luscher TF, Landmesser U (2010) Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J 31:1792–1801PubMedCentral CrossRef PubMed
  17.Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Cho YK, Nam CW, Hur SH, Jang Y, Hong MK (2013) Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol 111:1–5CrossRef PubMed
  18.Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, Hong MK, Cho YK, Nam CW, Hur SH, Choi JH, Song YB, Hahn JY, Choi SH, Gwon HC, Jang Y (2012) ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J 163:601–607CrossRef PubMed
  19.Nishinari M, Shimohama T, Tojo T, Shiono T, Shinagawa H, Kameda R, Aoyama N, Izumi T (2013) Two-week interval optical coherence tomography: imaging evidence on neointimal coverage completion after implantation of the endeavor zotarolimus-eluting stent. Catheter Cardiovasc Interv 82:E871–E878CrossRef PubMed
  20.Teramoto T, Ikeno F, Otake H, Lyons JK, van Beusekom HM, Fearon WF, Yeung AC (2010) Intriguing peri-strut low-intensity area detected by optical coherence tomography after coronary stent deployment. Circ J 74:1257–1259CrossRef PubMed
  21.Gonzalo N, Serruys PW, Okamura T, van Beusekom HM, Garcia-Garcia HM, van Soest G, van der Giessen W, Regar E (2009) Optical coherence tomography patterns of stent restenosis. Am Heart J 158(284–293):1
  
• 作者单位：Takehiro Hashikata (1)
  Taiki Tojo (1)
  Sayaka Namba (1)
  Lisa Kitasato (1)
  Takuya Hashimoto (1)
  Ryo Kameda (1)
  Takao Shimohama (1)
  Minako Yamaoka-Tojo (1) (2)
  Junya Ako (1)
  
  1. Department of Cardiovascular Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan
  2. Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  Cardiac Surgery
  Vascular Surgery
  Biomedical Engineering
  Interventional Radiology
  Ultrasound
  
• 出版者：Springer Japan
• ISSN：1615-2573

文摘

Incomplete neointimal coverage and malapposed struts after stenting are associated with increased risk of stent thrombosis. We aimed to evaluate neointimal coverage early after Resolute zotarolimus-eluting stent (R-ZES) implantation using optical coherence tomography (OCT). A total of 20 patients with de novo native coronary lesions with R-ZES were enrolled. Among these patients, 20 stented lesions in 19 patients were evaluated at 1, 2, and 3 months after R-ZES implantation. The strut apposition and neointimal coverage were evaluated by OCT. Neointimal hyperplasia (NIH) thickness and percentage of covered struts and the proportion of incompletely apposed struts were measured at 1-mm intervals. The mean percentages of covered stent struts were over 85 % within 3 months (88.4 ± 6.3 % at 1 month, 95.5 ± 5.5 % at 2 months, 93.6 ± 3.5 % at 3 months). The percentages of incompletely apposed struts were not significantly different among the groups (4.4 ± 4.2 % at 1 month, 1.9 ± 1.9 % at 2 months, 3.1 ± 2.2 % at 3 months, p = 0.51). Mean NIH thickness (38.9 ± 8.1 μm at 1 month, 70.6 ± 18.8 μm at 2 months, 54.1 ± 5.9 at 3 months, p = 0.0016) was thickest in the 2 months group. Most of all OCT findings within 2 months demonstrated neointimal coverage with low signal intensity. The neointimal coverage of ZES-R was over 85 % within 3 months. These data may support shorter requirement of dual antiplatelet therapy duration with R-ZES. Keywords Zotarolimus eluting stent Stent thrombosis Neointimal coverage Optical coherence tomography